A Phase I Trial of the IGF‐1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer

PURPOSE. This study evaluated the maximum tolerated dose or recommended phase II dose (RPTD) and safety and tolerability of the ganitumab and everolimus doublet regimen followed by the ganitumab, everolimus, and panitumumab triplet regimen. MATERIALS AND METHODS. This was a standard 3 + 3 dose escal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Vlahovic, Gordana, Meadows, Kellen L., Hatch, Ace J., Jia, Jingquan, Nixon, Andrew B., Uronis, Hope E., Morse, Michael A., Selim, M. Angelica, Crawford, Jeffrey, Riedel, Richard F., Zafar, S. Yousuf, Howard, Leigh A., O'Neill, Margot, Meadows, Jennifer J., Haley, Sherri T., Arrowood, Christy C., Rushing, Christel, Pang, Herbert, Hurwitz, Herbert I.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2018
Matèries:
Gastrointestinal Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058343/
https://ncbi.nlm.nih.gov/pubmed/29572245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0377
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars